Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R 12 or R 13 on the A group is an aryl, heteroaryl or heterocycle (R 32 ) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.
1. A process to prepare a compound of Formula I comprising:
a. converting a compound of Structure 1 into Structure 2;
b. deprotecting the compound of Structure 2; and
c. reacting the resultant compound with A-COOH to afford a compound of Formula I;
wherein the compound of Formula I is
the compound of Structure 1 is:
the compound of Structure 2 is:
Q 1 is C(R 1 R 1′ );
X 1 is N and X 2 is CH;
PG is a protecting group;
R 1 and R 1′ are independently chosen from hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, and C 1 -C 2 haloalkyl;
A is a group selected from:
R 5 and R 6 are independently selected from —CHO, —C(O)NH 2 , C 2 -C 6 alkanoyl, and hydrogen;
R 8 and R 8′ are hydrogen;
X 11 is N or CR 11 ;
X 12 is CR 12 ;
X 13 is CR 13 ;
X 14 is N or CR 14 ;
one of R 12 and R 13 is chosen from R 31 and the other of R 12 and R 13 is chosen from R 32 ;
R 31 is chosen from hydrogen, halogen, nitro, cyano, C 1 -C 2 haloalkyl, C 1 -C 2 haloalkoxy, C 1 -C 6 alkyl, —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), C 2 -C 6 alkenyl, C 2 -C 6 alkanoyl, C 1 -C 6 alkoxy, C 2 -C 6 alkenyloxy, C 1 -C 6 thioalkyl;
R 32 is selected from
R 11 and R 14 are independently chosen at each occurrence from hydrogen, halogen, nitro, cyano, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 2 -C 6 alkanoyl, C 1 -C 6 alkoxy, C 1 -C 6 thioalkyl, C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy;
L is
where R 17 is hydrogen, C 1 -C 6 alkyl, or —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), and R 18 and R 18′ are independently chosen from hydrogen, halogen, hydroxymethyl, and methyl; and m is 0, 1, 2, or 3;
B is a monocyclic or bicyclic carbocyclic; a monocyclic or bicyclic carbocyclic-oxy group; C 2 -C 6 alkenyl; C 2 -C 6 alkynyl; —(C 0 -C 4 alkyl)(aryl); or —(C 0 -C 4 alkyl)(heteroaryl); each of which B is unsubstituted or substituted with one or more substituents independently chosen from R 33 and R 34 , and 0 or 1 substituents chosen from R 35 and R 36 ;
R 33 is independently chosen from halogen, cyano, C 1 -C 6 alkyl, C 2 -C 6 alkanoyl, C 1 -C 6 alkoxy, C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy;
R 34 is independently chosen from nitro, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, and C 1 -C 6 thioalkyl;
R 35 is independently chosen from naphthyl, naphthyloxy, indanyl; each of which R 35 is unsubstituted or substituted with one or more substituents independently chosen from halogen, nitro, cyano, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkanoyl, C 1 -C 6 alkoxy, —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy; and
R 36 is independently chosen from tetrazolyl, (phenyl)C 1 -C 2 alkoxy, phenoxy, and 5- or 6-membered heteroaryl containing 1, 2, or 3 heteroatoms independently chosen from N, O, B, and S, each of which R 36 is unsubstituted or substituted with one or more substituents independently chosen from halogen, nitro, cyano, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkanoyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylester, —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy.
2. The process of claim 1 , wherein R 1 and R 1′ are independently chosen from hydrogen, halogen, and C 1 -C 6 alkyl.
3. The process of claim 1 , wherein R 31 is hydrogen.
4. The process of claim 1 , wherein R 32 is
5. The process of claim 1 , wherein R 17 is hydrogen.
6. The process of claim 1 , wherein B is —(C 0 -C 4 alkyl)(aryl) or —(C 0 -C 4 alkyl)(heteroaryl); each of which B is unsubstituted or substituted with one or more substituents independently chosen from R 33 and R 34 , and 0 or 1 substituents chosen from R 35 and R 36 .
7. The process of claim 1 , wherein B is —(C 0 -C 4 alkyl)(heteroaryl) which is unsubstituted or substituted with one or more substituents independently chosen from R 33 and R 34 .
8. The process of claim 1 , wherein R 33 is selected from halogen and C 1 -C 6 alkyl.
9. The process of claim 1 , wherein B is selected from:
10. The process of claim 1 , wherein R 32 is selected from
11. The process of claim 1 , wherein A is
12. The process of claim 1 , wherein A is
13. The process of claim 12 , wherein R 32 is
14. The process of claim 13 , wherein R 1 and R 1′ are independently chosen from hydrogen, halogen, and C 1 -C 6 alkyl.
15. The process of claim 14 , wherein R 6 is C 2 -C 6 alkanoyl.
16. The process of claim 15 , wherein B is —(C 0 -C 4 alkyl)(heteroaryl); each of which B is unsubstituted or substituted with one or more substituents independently chosen from R 33 and R 34 .
17. The process of claim 16 , wherein R 17 is hydrogen.
18. The process of claim 17 , wherein R 33 is selected from halogen and C 1 -C 6 alkyl.
19. The process of claim 15 , wherein B is selected from:
20. The process of claim 15 , wherein B is: